Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.

Paulo P, Ribeiro FR, Santos J, Mesquita D, Almeida M, Barros-Silva JD, Itkonen H, Henrique R, Jerónimo C, Sveen A, Mills IG, Skotheim RI, Lothe RA, Teixeira MR.

Neoplasia. 2012 Jul;14(7):600-11.

2.

Potential downstream target genes of aberrant ETS transcription factors are differentially affected in Ewing's sarcoma and prostate carcinoma.

Camões MJ, Paulo P, Ribeiro FR, Barros-Silva JD, Almeida M, Costa VL, Cerveira N, Skotheim RI, Lothe RA, Henrique R, Jerónimo C, Teixeira MR.

PLoS One. 2012;7(11):e49819. doi: 10.1371/journal.pone.0049819. Epub 2012 Nov 19.

3.

ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.

Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A, Albertini V, Malek A, Chiorino G, Catapano CV, Carbone GM.

PLoS One. 2010 May 10;5(5):e10547. doi: 10.1371/journal.pone.0010547.

4.

Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.

Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY.

Eur Urol. 2015 Oct;68(4):555-67. doi: 10.1016/j.eururo.2015.04.033. Epub 2015 May 8.

5.

FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer.

Paulo P, Barros-Silva JD, Ribeiro FR, Ramalho-Carvalho J, Jerónimo C, Henrique R, Lind GE, Skotheim RI, Lothe RA, Teixeira MR.

Genes Chromosomes Cancer. 2012 Mar;51(3):240-9. doi: 10.1002/gcc.20948. Epub 2011 Nov 12.

PMID:
22081504
6.

The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key?

Shaikhibrahim Z, Lindstrot A, Ellinger J, Rogenhofer S, Buettner R, Perner S, Wernert N.

Mol Med Rep. 2012 Feb;5(2):313-6. doi: 10.3892/mmr.2011.647. Epub 2011 Oct 27.

PMID:
22038307
7.

YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.

Rahim S, Beauchamp EM, Kong Y, Brown ML, Toretsky JA, Üren A.

PLoS One. 2011 Apr 29;6(4):e19343. doi: 10.1371/journal.pone.0019343.

8.

Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.

Ateeq B, Kunju LP, Carskadon SL, Pandey SK, Singh G, Pradeep I, Tandon V, Singhai A, Goel A, Amit S, Agarwal A, Dinda AK, Seth A, Tsodikov A, Chinnaiyan AM, Palanisamy N.

Prostate. 2015 Jul 1;75(10):1051-62. doi: 10.1002/pros.22989. Epub 2015 Mar 23.

9.

Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.

Boormans JL, Korsten H, Ziel-van der Made AJ, van Leenders GJ, de Vos CV, Jenster G, Trapman J.

Int J Cancer. 2013 Jul 15;133(2):335-45. doi: 10.1002/ijc.28025. Epub 2013 Feb 12.

10.

Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.

Lunardi A, Varmeh S, Chen M, Taulli R, Guarnerio J, Ala U, Seitzer N, Ishikawa T, Carver BS, Hobbs RM, Quarantotti V, Ng C, Berger AH, Nardella C, Poliseno L, Montironi R, Castillo-Martin M, Cordon-Cardo C, Signoretti S, Pandolfi PP.

Cancer Discov. 2015 May;5(5):550-63. doi: 10.1158/2159-8290.CD-13-1050. Epub 2015 Feb 4.

11.

ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer.

Kacprzyk LA, Laible M, Andrasiuk T, Brase JC, Börno ST, Fälth M, Kuner R, Lehrach H, Schweiger MR, Sültmann H.

PLoS One. 2013;8(3):e59976. doi: 10.1371/journal.pone.0059976. Epub 2013 Mar 29.

12.

ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.

Miyagi Y, Sasaki T, Fujinami K, Sano J, Senga Y, Miura T, Kameda Y, Sakuma Y, Nakamura Y, Harada M, Tsuchiya E.

Mod Pathol. 2010 Nov;23(11):1492-8. doi: 10.1038/modpathol.2010.149. Epub 2010 Aug 6.

13.

TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.

Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, Peltola M, Smit F, Verhaegh G, Schalken J, Nees M, Kallioniemi O.

Cancer Res. 2006 Nov 1;66(21):10242-6.

14.

High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer.

Smit FP, Salagierski M, Jannink S, Schalken JA.

BJU Int. 2013 May;111(5):836-42. doi: 10.1111/bju.12119.

15.

[Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].

Dai MJ, Chen LL, Zheng YB, Chen W, Tao ZH, Weng ZL, Wu XL, Li CD, Chen ZG, Chen XD, Shi SB.

Zhonghua Yi Xue Za Zhi. 2008 Mar 11;88(10):669-73. Chinese.

PMID:
18642766
16.

A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model.

Rahim S, Minas T, Hong SH, Justvig S, Çelik H, Kont YS, Han J, Kallarakal AT, Kong Y, Rudek MA, Brown ML, Kallakury B, Toretsky JA, Üren A.

PLoS One. 2014 Dec 5;9(12):e114260. doi: 10.1371/journal.pone.0114260. eCollection 2014.

17.

Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer.

Barros-Silva JD, Paulo P, Bakken AC, Cerveira N, Løvf M, Henrique R, Jerónimo C, Lothe RA, Skotheim RI, Teixeira MR.

Neoplasia. 2013 Jul;15(7):720-6.

18.

ERG upregulation and related ETS transcription factors in prostate cancer.

Rostad K, Mannelqvist M, Halvorsen OJ, Oyan AM, Bø TH, Stordrange L, Olsen S, Haukaas SA, Lin B, Hood L, Jonassen I, Akslen LA, Kalland KH.

Int J Oncol. 2007 Jan;30(1):19-32.

PMID:
17143509
19.

Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.

Mesquita D, Barros-Silva JD, Santos J, Skotheim RI, Lothe RA, Paulo P, Teixeira MR.

Oncotarget. 2015 Mar 10;6(7):5217-36.

20.

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM.

Science. 2005 Oct 28;310(5748):644-8.

Supplemental Content

Support Center